

**Supplementary Table S3.** Effect of the cannabinoids on the molecular entities, participating in the interaction between NK and target cells.

Receptor	Ligand	Activity	Effect of cannabinoids	Reference
<b>KIR</b>				
KIR2DL2/3	HLA-C1	I	THC upregulates KIR2DL2 RNA levels	<a href="#">151</a>
KIR3DL1	HLA-Bw4, HLA-A	I	THC (0.03 mg/kg) upregulates HLA-A expression	<a href="#">151</a>
<b>CD94-NKG2</b>				
NKG2C	HLA-E	A	THC increases NKG2 RNA expression	<a href="#">151</a>
NKG2E	HLA-E	A		
NKG2D	MIC-A, -B; ULBP1-4	A	Exposure to SR141716 increases glioma cells susceptibility to NK cell mediated cytotoxicity through the upregulation of NKG2D ligand MICA/B. NK cells exposed to CBD (10 $\mu$ M) does not exhibit any change in NKG2D	<a href="#">29, 148, 149</a>
<b>NCR5</b>				
NKp30	BAT-3, HSPG, B7-H6	A	THC (75 mg/kg) downregulates B7 (CD86) expression in lung mice cells.	<a href="#">152</a>
NKp44	VIRAL HA	A		
NKp46	VIRAL HA, HSPG	A	CB2 KO favors NK cell NKp46 expression within the tumor microenvironment	<a href="#">25</a>
LILR	MHC-I UL18	I	Cannabinoids differentially induce MHC-I expression in colorectal cancer cells: THC (27 $\mu$ M) 6.1-fold, CBDV (20 $\mu$ M) 5.5 fold, CBV (20 $\mu$ M) 3.9 fold, CBD (11 $\mu$ M) 3.3 fold, CBG (38.9 $\mu$ M) 2.7 fold, CBN (28 $\mu$ M) 1.8 fold, CBC (26 $\mu$ M) 1.6 fold. Synthetic cannabinoid SR141716 does not affect MHC-I in glioblastoma cells WIN55212-2 increases MHC-I in target cell	<a href="#">148, 153</a>
KLRG1	Cadherins	I	KLRG1 expression is downregulated in cannabis consumers. KLRG1 expression is dependent on CB2 expression	<a href="#">154, 155</a>
PILR	CD99	A	CBD (5 $\mu$ M) downregulates CD99 expression in MSCs	<a href="#">156</a>
PD1	PD1L	I	WIN55-212-2 increases PD-L1 in cancer cells	<a href="#">149</a>
CD69			O1602 favor CD69 overexpression, a functional marker triggering the NK cytotoxicity	<a href="#">31</a>
FasL	Fas	A	AEA induced FAS recruitment to plasma membrane in cancer cell; CBD promotes FasL expression; THC; JWH133 and SR141716 decreases Fas and FasL expression	<a href="#">157-160</a>
TRAIL	DR5	A	WIN55212-2 favors DR5 expression in TRAIL resistant cancers; CBD substantially upregulates TNF/TNFR1 and TRAIL/TRAIL-R2 signaling by modulation of both ligand and receptor levels	<a href="#">161, 162</a>